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ABSTRACT OF THESIS

DEVELOPMENT AND CHARACTERIZATION OF NOVEL MONOCLONAL
ANTIBODIES FOR STUDYING PRION PATHOGENESIS

Monoclonal antibodies (mAbs) recognizing different regions of PrP are potential
tools in the study of prion diseases and immunotherapy. We used shuffled
recombinant prion protein containing elk and mouse PrP as antigen to produce
monoclonal antibodies in mice. We found that mAb 5C6 mapped to a
discontinuous epitope comprised of amino acid 132 and 158 (mouse numbering).
Monoclonal anibody 9E9 which maps to a unique N-terminal epitope at amino
acid preferentially recognized cervid PrP. In contrast, the epitope of mAb 9H9 is
located in the C-terminus and only reacted with mouse and hamster. The epitope
for mAb 7H11 appears to be affected by the glycosylation of PrP and by the
presence or absence of the disulfide bond. To confirm the epitopes of these mAbs,
we constructed elk and mouse mutants both with and without reactivity to 5C6
and 9E9. We then used these mutants to investigate the effect of each epitope on
the conversion of PrPC to PrPsc. In one approach to map the epitopes of
newly-generated monoclonal antibodies (mAbs), we generated a series of
contiguous ten amino acids deletion constructs spanning amino acids 107 to 230
and expressed these recombinant proteins in mammalian cells (RK13) or
bacteria. Using Western blotting, all deletion constructs could be recognized with
antibodies to the extreme C-terminus of PrP, or the N-terminal region upstream of
the structured globular domain of PrP. However, mAb 5C6 failed to react with all
internally deleted PrP constructs expressed in mammalian cells, and to a lesser

extent bacterially produced mutant recombinant proteins. We confirmed the
surprising result using the well-defined antibodies 6H4 and D18, which recognize
epitopes in the same internal region as 5C6. Our results suggest the formation of
an ultra-stable, SDS-resistant conformation in PrP harboring deletions mutations
in the globular domain of PrP. We hypothesize that epitope burying within this
stable conformation(s) precludes mAb recognition by 5C6, 6H4 and D18. It will be
of extreme interest to determine the relationship of this previously undefined PrP
conformation to the pathogenic process of PrP conformational change.
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Chapter 1
Introduction

The Prion diseases
Prion diseases, also called transmissible spongiform encephalopathies
(TSEs), are a group fatal neurodegenerative diseases occurring in humans and
animals. They are characterized by the development of spongiform
degeneration associated with neuronal loss, reactive astrocytic gliosis, and
occasionally amyloid deposition in the brains of infected hosts. The cause of
prion diseases is an unconventional proteinaceous pathogen termed prion
(Prusiner 1982).

Unlike other infectious agents, the prion is resistant to many

physical and chemical treatments such as Ultraviolet irradiation, heat or
nucleases that are usually used to inactivate conventional pathogens.

After such

treatments, the infectivity of prions is not reduced (Alper, Cramp et al. 1967; Gibbs,
Gajdusek et al. 1978; Prusiner 1982). Currently, no therapies or cures are
available.

Prion diseases of humans are unique in that they can be inherited in an
autosomal dominant manner, occur sporadically, or result from infection. The
human diseases include Creutzfeldt-Jacob disease (CJD), kuru, fatal familial
insomnia (FFI), Gerstmann-Straussler-Scheinker disease (GSS), and variant CJD
(vCJD).

Approximately 85% of human prion disease are sporadic CJD which

occurs at a frequency of one to two cases per million people per year, usually
between the age of fifty to sixty years (Wadsworth J.D.F. 2007).
1

Kuru was the

first recognized that transmissible human prion disease.

Kuru occurs in the fore

linguistic group of eastern the highlands province of Papua New Guinea where
they have ritualistic cannibalism (Gajdusek, Gibbs et al. 1967).

Children and

women, who were the main consumers of elder tribe members’ brains, were most
often affected by kuru (Alpers and Gajdusek 1965).

Several familial human prion

diseases exist including FFI and GSS. These diseases account for 10% to 20%
of all human prion diseases. The age of clinical onset in familial prion diseases is
generally earlier, and the incubation time is longer than in sporadic prion diseases
(Collinge, Whitfield et al. 2008).

In the 1990s, several cases of CJD, termed

variant Cretuzfeld-Jakob disease (vCJD), were recognized in young adults,
generally in their early twenties, with a clinical presentation in which behavioral
and psychiatric disturbances predominated. Biochemical and neuropathological
data indicated a possible association with bovine spongiform encephalopathy
(BSE) in cattle (Bruce, Will et al. 1997; Hill, Desbruslais et al. 1997). To date with
approximately 200 individuals have developed disease, most of the cases were
occurred in Great Britain.

This unique feature has allowed retrospective studies

designed to determine the true frequency of disease, which suggests than many
more individuals are incubating the disease than have currently developed clinical
symptoms worldwide (Ironside, Hilton et al. 2000).

At present, there is a concern

that some individuals exposed to BSE might be asymptomatic carriers of
infectivity (Brandel, Delasnerie-Laupretre et al. 2000) and that these people might
pose a risk of further transmission of the infection to others (e.g., blood
transfusions, donors for corneal transplantations)

2

In animals, prion diseases can either occur naturally or as the result of
consumption of contaminated food and are more common than in humans. In
1986, a new prion disease occurring in cattle of United Kingdom was termed
Bovine spongiform encephalopathy (BSE). BSE is amplified through the bovine
food chain via eating feed containing rendered meat and bone meal contaminated
with bovine brain and spinal cord from infected cattle (Wilesmith, Ryan et al.
1991).

This disease has affected cattle worldwide after the first case in United

Kingdom.

In 1996, a variant CJD has been reported in humans (Will, Ironside et

al. 1996).

Extensive biochemical and pathogenetic evidence indicated that

vCJD is caused by consumption of with BSE-contaminated food.

Chronic Wasting Disease (CWD) which was first discovered at a research facility
in north central Colorado in 1967 is a TSE affecting mule-deer (Williams and
Young 1980), Rocky Mountain elk (Williams and Young 1982), white-tailed deer
(Spraker, Miller et al. 1997), black-tailed deer (Williams and Young 1980), and
moose (Baeten 2007).

This disease was identified as a TSE by identification of

neuronal vacuoles (Williams and Young 1980) and deposition of plaques or
aggregated prion protein in the brain (Spraker, Zink et al. 2002) These animals
contained prion infectivity in the brain (Williams and Young 1992; Browning,
Mason et al. 2004) and in skeletal muscle (Angers, Browning et al. 2006).

CWD

has rapidly spread to several states including New York and West Virginia from a
small region in southeastern Wyoming, northeastern Colorado, southwestern
Nebraska, and a small part of Canada (Sigurdson 2007). It has also been found
in imported elk in South Korea (Sohn, Kim et al. 2002). The distribution of the
3

disease in focal spots suggests the possibility that outbreaks may have occurred
as a result of spillover from infected game farms rather than spread as a result of
the natural movement of free-ranging animals (Sigurdson 2007).

CWD is the

only prion disease of wild animals that has been documented to be transmitted
horizontally.

The source and route of transmission are currently unknown (Miller,

Wild et al. 1998; Miller, Williams et al. 2000). Additionally, CWD is highly
contagious between cervids.

However its ability to transmit to other species is

not entirely clear, especially to those that share lands with CWD-affected cervids
or to humans consuming the meat of CWD-affected animals.

Scrapie is a natural prion disease of sheep and has existed over 200 years with
no evidence suggesting transmission to humans despite the existence of several
well-characterized strains (Bruce 1993). There are multiple environmental
sources of infection to transmit between sheep or flocks.

Transmissible Mink

Encephalopathy (TME) is a prion disease of mink that has been found
sporadically in farmed mink in several countries.
in Wisconsin and Minnesota (Eckroade 1973).

It was first recognized in 1947
TME has been experimentally

transmitted to several species including cattle (Hamir 2006), sheep and goats
(Hadlow 1987), monkeys (Eckroade 1970), skunks and ferrets (Eckroade 1973),
and raccoons (Eckroade 1973; Hamir, Miller et al. 2004). The most interesting
transmission of TME is from an affected mink in Wisconsin to hamsters.

After

serial passage, it presents with two distinct clinical profiles termed hyper (HY) and
drowsy (DY) (Bessen and Marsh 1992). These two strains of TME were found
with different transmission profiles and biochemical properties in hamsters
4

(Bessen and Marsh 1992).

Molecular biology of prion proteins (PrPC and PrPSc)
The normal form PrP, cellular prion protein (PrPC), is a molecule ubiquitously
expressed in mammalian cells.

It is synthesized in the secretory pathway on

endoplasmic reticulum (ER)-attached ribosomes as a 253 amino acid protein
before post-translational modification.

Mature PrPC is found as a glycosyl

phosphatidyl inositol (GPI) –linked glycoprotein with a disulfide bond which is
enriched in cell membrane and is highly conserved in mammals.

The N-terminal

region of this molecule is unstructured, but it still contains two defined and
conserved regions. The first region consists of five repeats amino acid
sequence called octa-repeat region (Riek, Hornemann et al. 1997; Smith, Drake
et al. 1997). This region has been proposed to be important in copper binding
and might be involved in prion pathogenesis (Brockes 1999). The second region
contains a highly hydrophobic profile, which was originally termed transmembrane
region 1(Hay, Barry et al. 1987; Shyng, Moulder et al. 1995).

The function of this

domain is still unclear, but it is relevant to prion pathology and necessary for PrPC
The carboxyl terminus of PrPC contains

α-cleavage (Lutz, Brabeck et al. 2010).

of three α- helices, and two anti-paralleled β- sheets.

There are two asparagine

residues that for glycosylation and two cysteine residues will form a disulfide bond
links α-helices two and three (Riek, Hornemann et al. 1996; Prusiner 1998; Harris
2003).

The pathogenic form PrP (PrPSc) is derived from PrPC and has identical

amino acid sequence with PrPC (Oesch et al., 1985; Chesebro et al., 1985; Stahl
et al., 1993).
5

PrPC is a high -helical content structure containing 42% -helix and 3% -sheet.
When PrPSc is formed, some of the -helix is converted into β-sheet. PrPSc is a
high -sheet construct contains 43% -sheet increasing from 3% (Caughey, Dong
et al. 1991; Pan, Baldwin et al. 1993; Pergami, Jaffe et al. 1996). Because of this
conformational transition, PrPSc has lower solubility in non-denaturing detergents,
a high tendency to aggregate and partial resistance to proteinase K (PK).
PrPrSc, PrPC is PK sensitive and detergent soluble (Table 1).

Unlike

Because of these

properties, the protease resistance of PrP is a way to distinguish the two forms of
PrP (Oesch, Westaway et al. 1985).

After treatment with PK, PrPSc is seen as

three bands: the di-glycosylated, mono-glycosylated, and un-glycosylated form in
western blot (Bolton, McKinley et al. 1982; Oesch, Westaway et al. 1985), while
PrPC is degraded.

Modification and trafficking in the cell
The processing of mature PrPC includes the cleavage of the N-terminal signal
sequence by a signal peptidase in the ER, removal of the C-terminal signal
peptide and replacement with a glycosylphosphatidylinositol (GPI) anchor,
formation of a disulfide bond between two cysteine residues, and glycosylation at
two asparagines (Prusiner 1998; Harris 2003).

PrPC is then delivered to the cell

surface and anchored to the outer leaflet of neurons and other cell types in lipid
rafts via the GPI anchor (Figure 1). PrPC is also recycled between the plasma
membrane and endocytic compartment (Shyng, Huber et al. 1993).

PrPC is

highly expressed on the surface of neurons and lymphocytes, but is also
6

expressed on dendritic cells and cells of the monocyte lineage (Kitamoto,
Muramoto et al. 1991). There are two other topological forms of PrPC that are
both in the transmembrane. One is found with the N-terminus in the lumen of the
ER and is called Ntm-PrP and the other is in the opposite orientation and called
Ctm-PrP (Hegde, Mastrianni et al. 1998).

Mature PrPC has a molecular weight of

approximately 33-35kD containing an N-terminal unstructured flexible region with
an octapeptide repeat that can bind copper and a C-terminal structured region
with three alpha helices and two short beta sheets (Figure 1.1).

Several studies indicate that the conversion of cellular PrPC to a protease
resistant PrPSc is a posttranslational event that occurs after the protein reaches
the lipid raft on the cell surface. (Caughey and Raymond 1991; Borchelt,
Taraboulos et al. 1992; Taraboulos, Raeber et al. 1992). The reason why PrPC
has to reach the membrane before it converted to PrPSc is still unknown. One
possibility might be the posttranslational modifications for PrPC are necessary for
its conversion after reaching the plasma membrane.

One possibility is PrPC

functions as a receptor that mediates PrPSc internalization during infection.
Alternatively the lipid and protein environment at the plasma membrane might be
favorable for the PrPC and PrPSc interaction and conversion, or a factor needed
for the transconformation could be localized specifically at the plasma membrane
(Prusiner 1998; Campana, Sarnataro et al. 2005).

When PrPC was transported to the cell surface, PrPC undergoes an
endoproteolytic cleavage event The C1 cleavage site (Chen, Teplow et al. 1995)
7

is located between 109/110 in mouse sequencing numbering, producing a
17-KDa C-terminal fragment. When PrPC is converted to PrPSc, the
conformational change of PrP makes the C1 cleavage site instead of a new
cleavage site termed C2 cleavage producing a 21-Kda C-terminal fragment. The
C2 cleavage site is between 88 and 89 in mouse numbering.

Function of PrP
PrPC has been found in several mammals, and is highly conserved (Harris, Lele et
al. 1993; Windl, Dempster et al. 1995). The expression of PrPC can be detected
in most tissues except in kidney and liver, and is particularly high expressed in the
central nervous system (Miele, Alejo Blanco et al. 2003).
expressed, but its function still remains unknown.

PrPC is ubiquitously

Several groups have

generated PrP knock out (Prnp-/-) mice in an effort to study the function of PrPC.
In 1992, Büeler group in Zurich deleted the open reading frame of Prnp gene to
create the Zurich I Prnp-/- mouse. The resulting mice were devoid of PrPC and
found to be developmentally normal (Büeler et al., 1992).

However, these mice

do display demyelination in the peripheral nervous system with age, but without
the development of clinical signs (Nishida et al., 1999). In 1994, another knock out
mouse model of PrnP-/- (Edinbugh) was generated and also developed normally
(Manson, Clarke et al. 1994).

Later, there was another Prnp-/- mice developed by

Sakaguchi group known as Prnp-/- (Nagasaki). This knockout mouse strain
involved deleting the open reading frame of PrnP gene and ~1Kb of the intron 5’
to the open reading frame including the splice acceptor site (Moore et al., 1999;
Sakaguchi et al., 1996).

This The deletion in the non coding region caused
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unusual intergenic splicing between the remaining PrP gene and a Prnd gene
encoding a protein called Doppel (Dpl), which is 16 kb downstream of the Prnp
locus (Moore, Lee et al. 1999). Mice did develop ataxia and loss of cerebellar
Purkinje cells with age (Sakaguchi, Katamine et al. 1996) but this was attributed to
the overexpression of Doppel, not the absence of PrPC (Moore et al., 1999;
Sakaguchi et al., 1996). The doppel protein shares 24% homology in amino acid
sequence with PrP, is primarily expressed in the testis, and is absent in the CNS
of wild type mice but present in the CNS of Nagasaki Prnp-/- mice (Silverman, Qin
et al. 2000).

Several studies demonstrated PrPC is an important factor for

developing Prion disease by examining the susceptibility of Zurich PrnP-/- mice to
scrapie (Büeler, Aguzzi et al. 1993).

However, PrP knockout mice are resistant

to prion disease after inoculation with prions (Büeler, Aguzzi et al. 1993; Prusiner,
Groth et al. 1993). But susceptibility can be restored after introducing PrPC into
these mice (Büeler, Aguzzi et al. 1993). These studies provide further evidence
that PrPC is required for the conversion process and formation of PrPSc.

Species Barrier
The species barrier or transmission barrier was thought to be caused by
differences in the primary sequence of host and donor PrP (Harris 1999; Horiuchi,
Priola et al. 2000). It refers to the restriction of transmission of prion diseases
between different species.

It depends on the species being infected and the

specific strain of TSE agent involved.

For example, mouse scrapie can be

transmitted to Syrian hamsters with a long incubation time (over 370 days) but
transmitted to mice with shorter incubation time (around 100 days) (Kimberlin and
9

Walker 1978).

The 263K hamster scrapie strain transmitted into Syrian

hamsters has 60-day incubation time, but there is no clinical disease observed
when it is transmitted to mice (Kimberlin, Walker et al. 1989). Mouse PrP and
Syrian hamster PrP differ at only 12 of 209 amino acids.

There are many

factors that influence the species transmission barrier. Understanding its
molecular basis and mechanism is valuable after the discovery that vCJD is the
result of a transmission of BSE from cattle to human (Collinge, Sidle et al. 1996;
Hill, Desbruslais et al. 1997). It raises concerns about the possibility of
transmission of prions from other species to humans, for example CWD from deer
and elk. The differences in primary sequence of PrP and prion strain are two
factors that contribute to the species transmission barrier.

Prion Strains and Polymorphisms
Prion strains are characterized by difference of incubation time, distribution of
pathological lesions that they produce in the central nervous system of recipient
animals and clinical symptoms. (Telling 2004; Angers, Kang et al. 2010). The
influence of genetic variability on susceptibility to disease and pathogensis has
been reported.

Susceptibility or resistance to scrapie in sheep is associated with

polymorphisms at codons 136 (A/V), 154 (R/H) and 171 (Q/R/H) of the sheep
Prnp gene (Elsen, Amigues et al. 1999).

Scrapie susceptibility is conferred by

the VRQ and resistance by ARR and AHQ polymorphisms.

ARQ and ARH are

with an intermediate situation. The polymorphisms in all species of cervids are
also currently investigated (Schatzl, Wopfner et al. 1997; O'Rourke, Baszler et al.
1998; Johnson, Johnson et al. 2003; O'Rourke, Spraker et al. 2004; Jewell,
10

Conner et al. 2005; Johnson, Johnson et al. 2006; Green, Browning et al. 2007;
Meade-White, Race et al. 2007).

One polymorphism found in elk is codon 132

encoding either methionine or leucine (Schatzl, Wopfner et al. 1997; O'Rourke,
Baszler et al. 1998). This polymorphism is important because this residue
corresponds to codon 129 in the human prion protein that has been shown the
susceptibility to vCJD (Collinge, Sidle et al. 1996).

Immunological approach to study prion diseases
Several anti-PrP antibodies have been produced to detect prions and diagnose
prion diseases via immunoblotting. The similarity in the primary sequence of
donor PrPSc in comparison to PrPC of the recipient species seems to play a crucial
role in the species barrier.

The monoclonal antibody 3F4 recognized amino

acids from position 109 to 112 in human PrP (Barry and Prusiner 1986; Kascsak,
Rubenstein et al. 1987) and has been one of the most commonly used tools in
studying prion disease.

It reacts strongly to human and hamster PrP and

requires two methionine residues at position 109 and 112 in human PrP.

PrP

from other species which lack one or both methionine residues does not react with
3F4.

Some groups introduced 3F4 epitope into MoPrP by replacing leucine 108

and valine 111 with methionines present in human and hamster PrP and have
demonstrated the 3F4 required these two methionines for recognition.

However,

because the epitope of 3F4 is close to the endoproteolytic processing site of PrP,
the introduction of this tag partially interfered with the conversion process and
substantially reduced the total consistent PrPSc accumulation in infected cells
(Priola, Caughey et al. 1994; Lund, Olsen et al. 2007).
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MAb L42 is another

antibody that reacts with PrPC in a broad range of species including sheep, cattle,
goat, pig, human, dog, cat, mink, rabbit, and guinea pig but not mouse and
hamster in immunoblotting analysis (Vorberg, Pfaff et al. 2000).

MAb L42 was

raised by immunization of mice with an oligopeptide covering the ovine PrPC
sequence 145-163 (corresponding to position 141-159 of murine PrP).

Some

groups were using antibody-based immunotherapy against prion disease.
However, the difficulty of using antibody to cure prion diseae in humans still needs
to overcome is host tolerance to PrPC (White, Enever et al. 2003).
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Thesis research
Monoclonal antibodies (mAbs) are indispensable in studying and diagnosing
prion diseases. It is also useful for immunotherapy. The goal of this project is
to produce and characterize novel monoclonal antibodies against PrP.

To

achieve the goal we used PCR-based method to shuffle and generate a novel PrP
structure containing mouse PrP and cervid PrP. We will be utilizing these novel
anti-PrP monoclonal antibodies to study the species barrier, conversion
mechanism of PrPC to PrPSc, and the secondary structure conformation.
The results section includes how we made a shuffled recombinant prion
protein composed of mouse and elk PrP. We used this mixed recombinant prion
protein as antigen to produce novel monoclonal antibodies in PrP-null mice. We
used the feature of conserved PrP sequence of variant species to screen our
hybridoma cells, we identified four monoclonal antibodies. We found that mAb
5C6 mapped to a discontinuous epitope comprised of amino acid 132 and 158
(mouse numbering).

Monoclonal anibody 9E9 which maps to a unique

N-terminal epitope at amino acid preferentially recognized cervid PrP.

In

contrast, the epitope of mAb 9H9 is located in the C-terminus and only reacted
with mouse and hamster.

The epitope for mAb 7H11 appears to be affected by

the glycosylation of PrP and by the presence or absence of the disulfide bond.
result section 2, in order to confirm the epitopes of these mAbs, we constructed
elk and mouse mutants both with and without reactivity to 5C6 and 9E9.

We

then used these mutants to investigate the effect of each epitope on the
conversion of PrPC to PrPsc. The results may provide new insights into the
biology of PrPC and PrPSc.
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In

In result section 3, it provides another approach to map monoclonal antibodies.
We generated a series of contiguous ten amino acids deletion constructs
spanning amino acids 107 to 230 and expressed these recombinant proteins in
mammalian cells or bacteria.

Using Western blotting, all deletion constructs

could be recognized with antibodies to the extreme C-terminus of PrP, or the
N-terminal region upstream of the structured globular domain of PrP. However,
mAb 5C6 failed to react with all internally deleted PrP constructs expressed in
mammalian cells, and to a lesser extent bacterially produced mutant recombinant
proteins. We confirmed the result using the well-defined antibodies 6H4 and
D18, which recognize epitopes in the same internal region as 5C6.

Our results

suggest the formation of an ultra-stable, SDS-resistant conformation in PrP
harboring deletion mutations in the globular domain of PrP. We hypothesize that
epitope burying within this stable conformation(s) precludes mAb recognition by
5C6, 6H4 and D18.

It will be of extreme interest to determine the relationship of

this previously undefined PrP conformation to the pathogenic process of PrP
conformational change.

14

Figure 1.1 Schematic diagrams of mouse PrP primary structure and its
posttranslational modifications. The N-terminal region of PrP is unstructured
and the C-terminal region is structured.
signal peptide (orange).

In the extreme N terminus is a secretory

Region 51-90 consists of 5 octarepeats, which was

suggested to play a role in copper binding (Brockes 1999).

The royal blue region

is the structured region containing 3 -helices denoted 1, 2, 3 in red and two
β-sheets denoted β1, β2 in red.

N-linked glycosylation site (Asn180, Asn196) is

indicated by two red hexagons.

Cysteines 178 and 213 form a disulfide bridge.

Glycosyl phosphatidyl inositol (GPI) anchor signal peptide is located at the end of
C-terminus and labeled green. There are two endoproteolytic cleavage sites, C1
and C2, indicated by arrows.

C1 cleavage site is located at position

His110/Val111 and will produce a ~17kDa C1 fragment. C2 cleavage site is
located at position Trp88/Gln89 and will produce a ~21kDa C2 fragment.
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Table 1. Comparison of PrP properties
PrPC

PrPSC

Soluble

Insoluble

-helix rich

-sheet rich

Proteinase- sensitive

Proteinase-resistance

monomers

aggregates
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Chapter 2
Materials and methods

Preparation of antigen using DNA shuffling
PCR amplification of elk and mouse PrP coding sequences: 100 ng of
recombinant plasmids (pCAGGS-MoPrP or pCAGGS-elkPrP) carrying elk or
mouse prion protein gene were amplified with pfu polymerase (Stratagene) as
following condition: pre-denaturation 95°C/3min; 95°C /40sec; 60°C /40sec;72°C
/60sec. PCR products were purified by running 1.2% agarose followed by column
purification (Premega). The concentration of purified PCR products was quantified
by running 1.2% agarose gel with DNA standard.
DNase I digestion of mixed MoPrP and elkPrP DNA fragments: 3 μg of mixted
PCR products of MoPrP and ElkPrP (1:1) was incubated at 15°C for 10 min, then
add 0.15 unit of DNase I(Roche), incubated at 15°C for 10min, the reaction was
terminated by adding 10μL of stop solution and inactivated DNase I at 96°C for
10min. The DNase I digested DNA was separated with 2% low-temperature
agarose gel (Invitrogen) along with 10-bp DNA ladder. DNA fragments with the
length from 10 to 300bp were purified with phenol/chloroform method.
Re-assembly of small DNA fragments: 30 μL of DNase I digested DNA fragments,
5 μL of Pfu Ultra buffer, 1μL of dNTP (Roche), 1μL of Pfu Ultra were mixed and the
volume was adjusted to 50μL with ddH2O. The re-assembly PCR were
performed for 45 cycles as the following conditions: 94°C/3min; 94°C/30sec; (27°C
+1°C/cycle) /1min; 72°C/(1min+4sec/cycle); the PCR product was maintained at
72°C for 10min and then stored at 4°C.
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PCR amplification of reassembled PCR products: The reassembled DNA
fragments were amplified with primers with the addition of EcoRV and BamHI at
5’ends of upstream or downstream primers for 35 cycles as the following
conditions: pre-denaturation 94°C/3min; 94d°C/45sec; 47°C with increase
0.7°C/cycle 1min; 72°C/1min. PCR products were kept at 72°C for 10min. The
shuffled DNA fragments were digested, purified and then inserted into
pIRESpuro3 vector.
PCR-RFLP prescreening the chimeric DNA: Bacterial Colony-PCR was
performed and PCR products were purified with Wizard DNA purification Kit
(Promega) and digested with StuI and AluI.
DNA sequencing: plasmids were extracted according to QIA miniprep protocol
(Qiagen), and sequenced with CEQ8000 instrument.
Cell cultures
Rabbit epithelial kidney RK13 cells (ATCC, Manassas, VA) were maintained in 5%
CO2 at 37 °C in DMEM with 10% FBS.
Constructs
The elk PrP or mouse PrP coding sequence was amplified by polymerase chain
reaction (PCR) with primers containing AflII and EcoRI restriction endonuclease
recognition sites at the 5’ and 3’ ends respectively. Digested amplicons were
inserted into AflII- and EcoRI-cleaved pIRESpuro3 vector (Clontech, Mountain
View, CA). Following confirmation of the elk PrP coding sequence in the
recombinant vector, RK13 cells were transfected with pIRESpuro3 containing elk
PrP, mouse PrP or empty vector to produce RKE, RKM and RKV cells
respectively.
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Generation of transfected cells
Cells were plated in 6-well plates one day prior to transfection. Transfection
mixtures were prepared by mixing 2 μg of plasmid and 6.3 μl of lipofectamine
2000 (Invitrogen, Carlsbad, CA) in Opti-MEM medium (Invitrogen, Carlsbad, CA).
Prior to addition of 200 μl transfection mixture, cells were rinsed with Opti-MEM.
Following addition of transfection mixtures, 0.8 ml of complete medium containing
10 % FBS was added to cell monolayers. Following passage to 10 cm plates 24 hr
later, transfected cells were grown in complete medium containing 1 µg/ml
puromycin. Selection medium was changed every 3 days.
Infection with brain homogenate in Cell culture
Cells (2 x 105) were split to 6 well plates one day before prion infection. 10 % brain
homogenates diluted in Opti-MEM medium to 0.2 - 2% were added to cell
monolayers, in a volume of 1 ml per well. After 5 h, 2 ml of Opti-MEM medium
containing 15 % FCS was added. Cells were split into 10 cm plates, followed by 2
more passages. Cell lysates were harvested at passage 3 for Western blotting.
Immunoblotting
RK13 Cell lysate:
Cultured cell were treated with cold lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
0.5% sodium deoxycholate, 0.5% Igepal CA-630) and total protein concentration
was determined by bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc.,
Rockford, IL). Lysates were either untreated or treated with 40 mg/ml proteinase K
(PK) for one hour at 50oC and the reaction was terminated with 4 mM phenyl
methyl sulfonyl fluoride (PMSF) in final concentration. PrPSc in cell culture lysates
was purified by centrifugation for 1 h at 100,000 x g at 4°C. Samples were boiled
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in the presence of SDS for 10 min prior to electrophoresis. Proteins were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) using 10% Tris-glycine gels, and electrophoretically transferred to
PVDF-FL membranes (Millipore, Billerica, MA). Membranes were blocked in
Tris-buffered saline with 0.05% Tween-20 and 5% non-fat milk, incubated with
anti-PrP monoclonal antibody (mAb) 6H4 (Prionics AG, Schlieren-Zurich), or other
in-house mAb followed by HRP-conjugated sheep anti mouse IgG secondary
antibody. Membranes were developed using ECL-plus detection (Amersham),
and analyzed by using a FLA-5000 scanner (Fuji).
Brain homogenate:
Animals whose death was obviously imminent were euthanized by CO 2 inhalation
and cervical dislocation. Brain tissues from sacrificed mice were isolated rapidly
on dry ice and stored frozen at -80°C. Ten % brain homogenates in phosphate
buffered saline (PBS) lacking calcium and magnesium ions were prepared on ice
by repeated passage through 18-, followed by 22-gauge needles. 10 % brain
homogenates were aliquoted and stored in -80°C. Total protein concentration was
determined by bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc.,
Rockford, IL). Equivalent amounts of total protein were boiled at 100 oC in an
equal volume of 4X sodium dodecyl sulfate (SDS) buffer (100 mM Tris HCl, 4%
SDS, 0.2 % bromophenol blue, 20 % glycerol) for 10 minutes. Boiled samples
were then electropheretically separated on a 12 % SDS-polyacrylamide gel
(acrylamide, SDS, ammonium persulfate and TEMED - Bio Rad). PK digestion of
brain homogenates were performed with the addition 2% sarkosyl and incubated
for 1 hr at 37 °C at a PK concentration of 40 µg/ml. Digestion was terminated by
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the addition of phenyl methyl sulfonyl fluoride (PMSF) to a final concentration of 4
mM.

Deglycosylation of PrP was achieved by digestion with recombinant

PNGase F for 1 hour at 37°C, as specified by the supplier (New England Biolabs,
Beverly, MA). Following the addition of 4x non-reducing SDS loading buffer,
samples were boiled for 10 minutes at 100 °C.

Proteins were resolved by 12%

SDS-PAGE and electrophoretically transferred to polyvinylidene fluoride (PVDF)
membranes for later development PVDF-FL membranes (Millopore) for
fluorescent scanning. Following electrophoretic transfer, membranes were
incubated for 45 min in 5% (w/v) low fat milk in Tris buffered saline containing
Tween 20 (TBST) to block non-specific protein binding.

Membranes were

probed two hours at 4 °C with monoclonal antibody and incubated 1 hour at room
temperature with horse raddish peroxidase (HRP)-conjugated goat anti-Mouse
secondary antibody.

Blots were developed using ECL-Plus detection

(Amersham Biosciences, Piscataway, NJ) and analyzed by using a FLA-5000
scanner (Fuji).
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Chapter 3
Results

Section 1: Production and Characterization of monoclonal antibodies

A. Generating immunogen containing murine and cervid PrP using DNA
shuffling
Many anti-PrP antibodiest have been produced.

To create anti-PrP monoclonal

antibodies with novel epitopes, we generated new PrP sequences by
reassembling the sequences of two different species in vitro.

The similarity

between mouse and elk PRNP coding sequence is 81.54% and protein similarity
is 85.56% (Figure 2.1). Dr. Jifeng Bian, a scientist in our laboratory, used
polymerase chain reaction (PCR) to amplify mouse and elk PRNP coding
sequences.

He digested the PCR products with DNase I to generate a random

pool of fragments.

These fragments were reassembled by repeated cycles of

annealing in the presence of DNA polymerase.
overlapping.

Some of these fragments were

Recombination can occur when a fr fragment from one specie

becomes the template for a fragment from the other, and vice versa, causing
template switch (Stemmer 1994; Stemmer 1994). With the resulting chimeric
PrP constructs, we were able to produce a panel of antibodies which can
recognize mouse PrP, elk PrP or both.

Roughly one hundred sequences

containing mouse and elk PrP were produced. There are 30 amino acids which
differ between mouse and elk PrP sequence. Three constructs, shuffled PrP #3,
#34 and #68, with equal distribution of mouse and elk PrP sequence, were
chosen for immunization.

In Figure 2.1, red squares represent mouse PrP
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sequence and green squares represent elk PrP sequence. The middle
sequence is shuffled PrP #68, with mouse PrP sequence above and elk PrP
sequence below for reference. Of the 30 amino acids which differ between mouse
and elk, this chimera share 14 with mouse PrP and 16 with elk PrP.

In order to generate recombinant shuffled protein, Dr. Hae-Eun Kang, a postdoc
in our laboratory, cloned these three shuffled PrPs into pET-100/D-TOPO vector
(Invitrogen) containing polyhistidine site and enterokinase (EK) recognition site in
the N-terminus. She utilized the polyhistidine site to purify recombinant protein
with Ni-NTA resin. After purification, she used EK, which cleaves at the
C-terminus of the EK recognition site, to remove N-terminal tags without leaving
extraneous amino acid residues on the shuffled protein (Figure 2.2).

B. Screening of hybridoma cells
Fusing myeloma cells with spleen cells from a mouse that has been immunized
with the desired antigen is a popular method to produce monoclonal antibodies
(Kohler and Milstein 1975).

In our study, we reassembled PrP sequences and

chose three constructs containing an equal percentage of the elk and mouse PrP
sequences. We expressed these constructs in bacteria, purified them, and used
them as immunogen.

In order to achieve an immune response, PrP-null mice

(Prnp−/−) were used (Bueler, Fischer et al. 1992).
immunize two PrP-null mice.

Each shuffled PrP was used to

Freund's complete adjuvant (CFA) was used to

emulsify the antigen. CFA is effective in stimulating immunity and may increase
the production of immunoglobulins. After immunization, we collected blood and
23

detected the immune response via enzyme-linked immunosorbent assay (ELISA).
It was found that one mouse immunized with shuffled PrP #68 had an increased
immunogenic response to PrP (Figure 2.3) and she spleen cells from this mouse
were collected.

After fusion of spleen cells with myeloma cells, we selected a

series of hybridoma cells producing monoclonal antibodies recognizing
recombinant mouse PrP (rMoPrP) or elk PrP (rElkPrP) in the ELISA.

Screening

of hybridomas revealed several antibodies that reacted strongly against
recombinant PrP in the ELISA and western blot.

Four of the antibodies that had

strong reactivity were picked for further characterization. They are hybridoma
cell lines 5C6, 9E9, 7H11 and 9H9.
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Figure 2.1 Comparing primary structures of mouse PrP, elk PrP and shuffled
PrP. This figure is to show the different sequencing result between mouse and
elk PrP in primary structure and the distribution of these two species PrP in the
shuffled PrP #68. The top is mouse PrP sequence and the bottom is elk PrP
sequence. The middle sequence is our shuffled PrP #68. The difference between
mouse and elk PrP is indicated by a red box (mouse) or a green box (elk). The
amino acid sequence of shuffled PrP #68 was labeled as indicated. The
numbering was designated in elk numbering. The locations of secondary structure
are indicated by brown arrows (beta-sheet) and blue ribbons (alpha-helix).
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Figure 2.2 SDS-PAGE analysis of purified shuffled PrP recombinant protein.
‘E’ is eluted PrP with His in urea buffer at pH4.5. ‘Su’ is recombinant PrP in
NaOAc buffer at pH5.9 after EK treatment. ‘Pt’ is precipitated recombinant PrP in
NaOAc buffer at pH4.5 after EK treatment. ‘C’ is control without EK treatment. The
PAGE was stained (a)coomassie blue, or blotted with (b) mouse monoclonal
antibody anti-PrP 6H4 with 1:10,000 dilution or (c) His-probe.
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Figure 2.3 Titration of anti-PrP antibodies in the immunized mice. 96 well
ELISA plate was coated with 100ul of 1µg/ml recombinant shuffled PrP solution
per well. Blood serum was prepared from immunized mouse tails. Color
development was done with ABST peroxidase solution, and the absorbance of
samples was measured at 405 nm in ELISA plate reader. The x-axis is the dilution
factor of the serum. Blue Square indicates the response of one immunized mouse
with shuffled PrP#68. Red triangle represented second mouse immunized with
shuffled PrP#68. Grey triangle represents mAb 6H4 as a control.
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C. Characterization of anti-PrP monoclonal antibodies
To determine further specificity of the anti-PrP mAbs, western blot and
immunohistochemical analyses were performed.

Mammalian PrP (being 95%

conserved) has a higher homology of amino acid sequences as compared to PrP
in other species (Oesch, Westaway et al. 1985; Robakis, Sawh et al. 1986). To
characterize these antibodies, we utilized transgenic (Tg) mouse brain
homogenates, which were engineered to express PrPs from different species.
Tg(MCerB+C) is a transgenic line containing mouse residues predicted to
associate with hypothetical mouse protein X and cervid residues predicted to
interact with PrPSc from cervids with CWD. All brain homogenates were
prepared with 10% w/v sterile PBS lacking Ca2+and Mg2+. The total protein
content was measured by bicinchoninic acid assay (BCA).

The non-diluted

supernatant of the hybridoma cell culture was used as the first antibody.

The

previously characterized anti-PrP monoclonal antibody (MAb) 6H4 (Korth, Stierli
et al. 1997) was used as a positive control. MAb 6H4 recognizes a single linear
epitope, DYEDRYYRE, corresponding to positions 144–152 of human PrP. The
mAb 6H4 reacted with 10% brain homogenates from a broad range of various Tg
mice (Figure 2.4).
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Figure 2.4 Western blot analysis of various Tg mouse brain homogenates
with 6H4. All Transgenic mouse brain homogenates were prepared with 10% w/v
sterile PBS lacking Ca2+and Mg2+. Total protein content was measured by
bicinchoninic acid assay (BCA). Each lane was loaded with 25 µg brain
homogenate. KO is represented with Tg Prnp-/- background mice, and is a
negative control. Tg(MoPrP)4112 expresses high levels of mouse PrP in the
knockout background. Tg(DeerPrP)1536 expresses deer PrP on the knockout
background whereas Tg(ElkPrP)5037 expresses elk PrP, Tg(BoPrP)3705
expresses bovine, Tg(OvPrP-ARQ)3533 expresses one sheep allele of PrP, with
arginine at residue 136 and Tg(OvPrP-VRQ)4166 expresses sheep PrPC with
valine instead. Tg(EqPrP)5525 expresses horse PrPc on knockout background.
Tg(HuPrP-M129)6816 expresses human PrP with methionine at residue 129 in
knockout background mouse whereas Tg(HuPrP-V129)7826 expresses valine
in residue 129. Tg(MCerB+C)849, is a chimeric line which expresses the mouse
residues predicted to associate with mouse protein X and the cervid residues
predicted to interact with PrPSc from cervids with CWD. Membrane was probed
with mAb 6H4 in 1:10000 dilution, a comercial anti-PrP monoclonal antibody.

29

1) Monoclonal Antibody 5C6
To characterize the reactivity of 5C6 with PrP from different species, we prepared
10% brain homogenates from Tg mice expressing various PrPC sequences
including mouse PrP, deer PrP, elk PrP, bovine PrP, sheep PrP, equine PrP, and
human PrP.

From the western blot analysis, mAb 5C6 did not react with sheep

PrP(VRQ), which has a polymorphism at residue 136 with sheep(ARQ) (Figure
2.5A).

According to Figure 2.4, there is PrP expression in the brain homogenate

of sheep (VRQ).

Our collaborator, Dr. Jason Bartz, helped us to further

characterize 5C6 by probing samples from his laboratory.

He found that mAb

5C6 reacted with brain homogenates of a hamster, mink, ferret and cow, but did
not react with a squirrel monkey brain homogenate (Figure 2.5B). Based on the
western blot analysis with Tg mouse homogenates and other mammals’ brain
homogenates, 5C6 can efficiently recognize mouse, elk, deer, cow, sheep (ARQ),
human and horse PrP. Sheep (VRQ) and squirrel monkey have no reactivity
with 5C6.

According to these results and comparing the primary structure of

various mammals, the epitope of mAb 5C6 requires alanine and asparagine in
positions 132 and 158 of mouse PrP, respectively. (Figure 2.6)
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Figure 2.5 Western blot analysis to assess 5C6 epitope via brain
homogenates of (A)Tg mice and (B)other mammals. (A) 25 µg transgenic
mouse brain homogenate was loaded in each lane. KO is represented with Tg
Prnp-/- background mice, and is a negative control. All abbreviations for the
transgenic lines can be found in the previous figure legend. Membranes were
probed with mouse monoclonal Ab 5C6. (B) From Bartz Lab. 500µg brain was
loaded in each lane. Each lane is representative brain homogenate of hamster,
mink, ferret, squirrel monkey or cow.
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Figure 2.6 Prion protein sequence alignment of various mammals and
shuffle PrP #68 in order to assess 5C6 epitope. Numbers at top indicate
mouse number amino acid sequence. The black bar at the bottom indicates
secondary structure, 1, 1 and partial 2 sequentially. Light blue shows one
epitope of 5C6 at residue 132 in MoPrP, a polymorphism for ovine PrP. The
unique amino acid valine from sheep (VRQ) is labeled circled in red. The other
epitope of 5C6 at residue 158 in MoPrP is indicated by royal blue. The unique
amino acid, serine, from squirrel monkey PrP, is circled in red.
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2) Monoclonal Antibody 9E9
We also used 10% brain homogenates from Tg mice expressing various PrPC
sequences to assess the epitope of the mAb 9E9.

Compared with 6H4 in Figure

2.4, the mAb 9E9 reacted with 10% brain homogenates from Tg mice expressing
deer PrP, elk PrP, bovine PrP, sheep PrP, and has weak binding to equine PrP.
MAb 9E9 did not react with either mouse PrP, human PrP or Tg (MCerB+C)
(Figure 2.7). When we aligned the PrPC sequences from various species, we
found two possible epitope regions for mAb 9E9.

One is located before the C2

cleavage site, and the other one is between the C1 and C2 cleavage sites.

In

order to assess the epitope of mAb 9E9, we removed Asn-linked glycans by
treating brain homogenates with N-glycosidase F (PNGase F).

PNGase F is an

amidase that cleaves the innermost GlcNAc from asparagine residues on
N-linked glycoproteins.

If the epitope of 9E9 is located before the C2 cleavage

site, we expected to detect the full length of PrP with 9E9 after PNGaseF
treatment.

If the epitope of 9E9 is located between the C1 and C2 cleavage sites,

we expected to detect the full length and C2 fragment of PrP with 9E9 after
PNGaseF treatment.

To detect the PrP fragment after treatment with PNGase F,

we used mAb 6H4 as a control.

MAb 6H4’s epitope lies between amino acid

residues 144 and 152. We expected it would recognize full-length PrP, 21 kDa C2
fragment, and 17kDa C1 fragment after treatment (Figure 2.8A).

In the western

blot analysis, mAb 9E9 recognized full length PrP and the 21 kDa C2 fragment,
but not the 17 kDa C1 fragment (Figure 2.8B).

According to the western blot

analysis results, we confirmed 9E9 has no reactivity with mouse PrP and we
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narrowed down the eiptope of mAb 9E9 to the C1 and C2 endoproteolytic
cleavage sites from amino acid 89 to 109 in mouse numbering shown in the box
(Figure 2.9).

Compared to the amino acids sequence of various species, mAb

9E9 recognizes CerPrP sequence between C1 and C2 cleavage site but fails to
recognize MoPrP due to the insertion of a glycine at positions 93 of MoPrP
(Figure 2.9).

9E9 has weak binding reactivity with horse and sheep PrP

compared to 6H4. Both horse and sheep PrP have a unique amino acid serine, at
position 94 as compared to the other mammals which react with 9E9.
influence the reactivity of 9E9 with horse and sheep PrP.
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This might

Figure 2.7 Western blot analysis of assessing 9E9 epitope via brain
homogenate of Tg mice. 40 µg transgenic mice brain homogenate was loaded in
each lane. KO is represented with Tg Prnp-/- background mice, and is a negative
control. Tg(MoPrP)4112 shows no reactivity with 9E9, nor does the chimeric
Tg(MCerB+C) or the human lines, Tg(HuPrP-M129) and Tg(HuPrP-V129).
Tg(DeerPrP,Tg(ElkPrP) and Tg(BoPrP) show reactivity with 9E9.
Tg(OvPrP-ARQ), Tg(OvPrP-VRQ) and Tg(EqPrP) show reduced 9E9 binding.
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Figure 2.8 Western blot analysis of effect of PrP processing on mAb
reactivity. Samples were either untreated (-) or treated (+) with PNGase F or
proteinase K as indicated. FVB is a wild type mouse with endogenous PrP.
Infected FVB is wild type mouse adapted RML. Tg(ElkPrP) is transgenic line 5037,
expressing elk PrP in knockout background mouse. Infected Tg(ElkPrP) was
Tg(ElkPrP) mouse adapted CWD isolate 092. PNG: PNGase F. PK: proteinase K.
F: Full length of PrP; C2: 21kDa C2 fragment; C1: 17kDa C1 fragment. The blot
was probed with (A) anti-PrP mAb 6H4 (B) anti-PrP mAb 9E9. The secondary
antibody is anti-mouse in 1:5000 dilution. (performed by Eri Saijo)
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Figure 2.9 Prion protein sequence alignment of various mammals and
shuffle PrP #68 in order to assess 9E9 epitope. Numbers at top indicate mouse
number amino acids sequence. The proteolytic cleavage sites are indicated with
arrows. C1 cleavage site is between 110/111. C2 cleavage site is between 88/89.
According to the western blot analysis of treatment with PNGase F, we narrowed
down the epitope of mAb 9E9 as located between C1 and C2 cleavage sites.
Glycine at position 93 in mouse and human PrP blocks the reactivity with 9E9.
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3) Monoclonal Antibody 7H11
To detect the reactivity of mAb7H11, we used the same 10% brain homogenates
from Tg mice expressing various species PrPC.

MAb 7H11 reacted with mouse

PrP, deer PrP, elk PrP, sheep PrP, equine PrP, human PrP and Tg (McerB+C),
but did not react with bovine PrP (Figure 2.10). The binding capacity of mAb
7H11 with Tg(Hu-PrP) on western blot seems weaker than other species. When
comparing the bovine PrP sequence with other mammals PrP sequences, bovine
PrP has a unique amino acid, glutamic acid, at residue 197 in bovine PrP
numbering.

Because this glutmaic acid is located between two N-linked glycans,

we think these two N-linked glycans might have a hindrance effect on the binding
ability of 7H11. In order to detect the effect between the reactivity of mAb 7H11
and N-linked glycans, un-infected and infected Tg mouse brain homogenates
were subjected to PNGase F or proteinase K treatment.

For infected brain

homogenates treated with PK, we expected to see three bands; Di-glycosylated
form, mono-glysylated form and un-glycosylated form PrP.

Comparing the lane

loaded with infected brain homogenate treated with PK from Figures 2.11 A and B,
we can observe that mAb 6H4 recognized three forms of PrP but mAb 7H11 failed
to recognize the di-glycosylated form of PrP from infected brain homogenates
after PK treatment. This result indicates that the reactivity of mAb 7H11 is
blocked by the presence of N-linked oligosaccharides.

The weak reactivity

between mAb 7H11 and Tg(HuPrP) brain homogenate, is likely due to the
presence of histidine in the human residue at the site homologous to
166 in bovine.

residue

In the other species, as well as our shuffled immuogen, this

residue is tyrosine. Also, the amino acid of interest, glutamic acid, is located
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thirty amino acids downstream of the sequence in the disulfide bond region. We
think the disulfide bond might be involved in the binding reactivity of mAb 7H11.
To assess the effect of the disulfide bond, two sets of brain homogenate samples
were prepared. One set of samples was mixed with loading buffer containing
reducing agent (2-Mercaptoethanol) the other set without.

Surprisingly, mAb

7H11 had a stronger reaction with the samples lacking the reducing agent (Figure
2.12). Based on these two observations, I hypothesize the epitope of mAb 7H11
is conformational and is sterically hindered by N-linked oligosaccharides. To
elucidate my hypothesis, I prepared four samples treated with reducing agent
and/or PNGase F. The presence of reducing agent did have an effect on mAb
7H11 binding.

Samples that were not treated with reducing agent had a stronger

reactivity with mAb 7H11 (Figure 2.13 A and B). Removing the N-linked
oligosaccharides via PNGase F (Fig2.13 C and D) had no effect on 7H11 binding
capacity.
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Figure 2.10 Western blot analysis of assessing 7H11 epitope via brain
homogenate of Tg mice. Each lane was loaded with 50µg transgenic mice brain
homogenate. KO is represented with Tg Prnp-/- background mice, and is a
negative control. 7H11 reacted with mouse PrP, deer PrP, elk PrP, sheep PrP,
equine PrP, and Tg (McerB+C), weakly with human PrP and did not react with
bovine PrP. This blot is probed with hybridoma cell supernatant 7H11. The
secondary antibody is anti-mouse in 1:5000 dilution.
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Figure 2.11 Effect of PrP processing on mAb 7H11 reactivity. Samples were
either untreated (-) or treated (+) with PNGase F or proteinase K as indicated.
FVB is a wild type mouse with endogenous PrP. Infected FVB is wild type
mouse adopted RML. Tg(ElkPrP) is transgenic line 5037, expressing elk PrP in
knockout background mouse. Infected Tg(ElkPrP) was Tg(ElkPrP) mouse
adapted CWD isolate 092. PNG: PNGase F. PK: proteinase K. Di-: di-glycosylated
form PrP; Mono-: mono-glycosylated form PrP; Un-: un-glycosylated form PrP.
The blot was probed with (A) anit-PrP mAb 6H4 (B) anti-PrP mAb 7H11. The
secondary antibody is anti-mouse in 1:5000 dilution. (performed by Eri Saijo)
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Figure 2.12 Effect of reducing agent on 7H11 binding.
In order to see the effect of reducing agent on 7H11 binding, samples were
treated with or without beta-Mercaptoethanol. (A) Samples were not treated with
beta-Mercaptoethanol and (B) Samples were treated with beta-Mercaptoethanol.
KO refers to mice in which the prnp coding sequence is disrupted and express no
PrPC, and is a negative control. All other transgenic lines are as previously
described. 7H11 binding was stronger under non-reducing conditions. 10ul from
10% brain homogenate
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Figure 2.13 Effect of PrP processing and reducing agent on mAb 7H11
reactivity. In order to see the effect of reducing agent and glycosylation site,
samples were treated with reducing agent beta-Mercaptoethanol or PNGase F.
KO refers to mice in which the prnp coding sequence is disrupted and express no
PrPC, and is a negative control. FVB is indicated wild type mouse brain
homogente. Tg(DeerPrP) is transgenic line 1536, expressing deer Prion in mouse.
Tg(ElkPrP) is transgenic line 5037, expressing elk PrPc in knockout background
mouse. Tg(BoPrP) is transgenic line 3705, expressing bovine PrPc in knockout
background mouse. Tg(HuPrP-M129) is transgenic line 6816, expressing human
PrPC with amino acid methiomine in 129 in knockout background mouse.
Tg(HuPrP-V129) is transgenic line 7826, expressing human PrPc with amino acid
valine in 129 in knockout background mouse. S.Hamster is syrian hamster brain
homogenate, 10µl from 10% brain homogenate (A) No treatment (B) samples
were treated with beta-Mercaptoethanol (C) samples were treated with PNGase F
only. (D) Samples were treated with beta-Mercaptoethanol and PNGase F. These
blots were probed with 7H11.
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Figure 2.14 Prion protein sequence alignment of various mammals and
shuffle PrP #68 in order to assess 7H11 epitope. Numbers at top indicate
mouse number amino acids sequence. The glycosylation sites are designated by
green hexagons, and highlighted in green boxes. The black bars at the bottom
indicate secondary structure, partial -helix 1, -sheet 2, -helix 2 and partial
-helix 3 sequentially. Disulfide bridge which linked -helix 2 and -helix 3 is
indicated in red lines. According to the western blot analysis, mAb 7H11 failed to
recognize bovine PrP (cow) which has a unique amino acid is located between
two N-linked glycosylation sites. Amino acids labeled with red circle indicate the
potential epitope of 7H11.
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4) Monoclonal Antibody 9H9
In western blots analysis, the mAb 9H9 reacted with 10% Tg mouse brain
homogenates expressing mouse PrP and Tg (McerB+C), but did not react with
cervid PrP, bovine PrP, ovine PrP, equine PrP and human PrP (Fig 2.15A).

MAb

9H9 also recognized PrP in Syrian hamster brain homogenate, but did not react
with mink PrP, ferret PrP, squirrel monkey PrP and cow PrP (Figure 2.15B,
performed by Dr. Jason Bartz lab).

Based on the western blot analysis of Tg

mouse homogenates and brain homogenates of other mammals, mAb 9H9 is
specific to mouse and Syrian hamster PrP. Comparing the sequences of various
mammals and shuffled PrP #68, we conclude that the epitope of mAb 9H9 is at
the C-terminus of mouse PrP (Fig 2.16).

Table 2 shows the summary of our in-house monoclonal antibodies reactivity with
various species.
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Figure 2.15 Western blot analysis of assessing 9H9 epitope via brain
homogenate of (A)Tg mice and (B)mammals. (A) 50 ug transgenic mice brain
homogenate was loaded in each lane. This blot is probed with 9H9. The
secondary antibody is anti-mouse in 1:5000 dilution. Reactivity is seen with
mouse and chimeric PrP only. (B) This blot was done by Dr. Jason Bartz Lab.
500ug brain was loaded in each lane.Each lane is reprsented hamster, mink,
ferret, squirrel monkey and cow sequentially.
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Only hamster shows reactivity.

Figure 2.16 Prion protein sequence alignment of various mammals and
shuffled PrP #68 in order to assess 9H9 epitope. Numbers at top indicate
mouse sequence number. According to western blot analysis, mAb 9H9 only
has reactivity with mouse and Syrian hamster. Blue box is showing the unique
sequence in mouse and hamster is same as our immunogen, shuffled PrP #68.
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Table 2 summary of mAbs reactivity with various species
5C6

9E9

7H11

9H9

Mouse
Deer
Elk
Bovine
Ovine ARQ
Ovine VRQ
Equine
Human M129

+
+
+
+
+
+
+

+
+
+
+
+
+
-

+
+
+
+
+
+
Weak

√
-

Human V129
Hamster
Mink
Ferret
Squirrel Monkey

+
+
+
+
-

ND
ND
ND
ND

Weak
ND
ND
ND
ND

+
-

“-“indicates no reactivity. “+” indicates positive reactivity. ND indicates not
determined.
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Section 2: Epitope tagging
As described in the introduction, pathogenesis in prion diseases is mediated by
abnormal folding of prion protein from alpha-helix rich form PrPC to beta-sheet rich
form PrPSc.

Unfortunately, the mechanism of conversion from PrPC to PrPSc is

still unclear.

Since we have generated these novel monoclonal antibodies, we

can utilize them, in conjunction with epitope tagging, to track PrPC trafficking
which could elucidate the conversion process.

We also can confirm these

monoclonal antibodies epitopes by insertion or elimination of the epitopes
predicted in section 1.

All mutated PrPs were created via mutagenesis and

transfected into rabbit kidney epithelial cells (RK13 cell) which do not express
endogenous PrPC.

Table 3 shows a summary of the constructs we made derived

from elk, mouse, and bovine PrP and their reactivity to our in-house monoclonal
antibodies.

49

Table 3. Summary of constructs derived from elk, mouse, and bovine PrP
and their reactivity to various monoclonal antibodies.
Elk

5C6

Mouse

+

-

+

-

+

-

wild type

A133V

wild type

A132V

wild type

N/A

wild type

N/A

N/A

Q185E

E197Q

N162S

9E9
7H11

Bovine

wild type

93G

N/A

N/A

N158S
93G

E197Q-H166Y

9H9

QR230DGRR

wild type

wild type

N/A

N/A

wild type

QR230RR
QR230DGRR

Table 3. The top row indicates the PrP species from which the constructs are
derived. The second row indicates positive (+) or non (-) reactivity of the
constructs to the mouse monoclonal antibodies indicated on the left (5C6, 9E9,
7H11, 9H9). ‘Wild type’ indicates the original PrP of the species in the
corresponding column. ‘N/A’ indicates data not available. Substitution mutant
nomenclature is as follows: ‘A133V’ indicates that Alanine in 133rd position in elk
PrP is substituted with Valine. Addition of a residue is described as follows:
‘93G’ indicates that a Glycine was inserted after the 93rd position in elk PrP.
Deletion of a residue is described as follows: ‘93G’ indicates that a Glycine was
deleted from the 93rd position of mouse PrP.
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A. The substitution of residue 132 in mouse PrP affects the susceptibility of
RML infection in cell culture model
Mutating the proposed amino acids of the 5C6 epitope is one way to confirm that
these amino acids are required for 5C6 recognition.

As described in result

section 1, the epitope of mAb 5C6 is located at amino acids 132 alanine and 158
asparagine (in mouse numbering) (Figure 2.6).

In order to differentiate various

PrPs we eliminated the 5C6 epitope by mutating the alanine to valine at residue
132, or asparagine to serine at residue 158 in mouse PrP.

These constructs are

referred to as MoPrP-A132V and MoPrP-N158S. The corresponding amino
acids were mutated in elk PrP to eliminate the 5C6 epitope: alanine to valine at
residue 133 or asparagine to serine at residue 162. These constructs are
referred to as ElkPrP-A133V and ElkPrP-N162S. To generate stable cell lines
expressing PrPs of interest, RK13 cells were transfected with wild type mouse PrP,
MoPrP-A132V, MoPrP-N158S, wild type elk PrP, elkPrP-A133V or elkPrP-N162S
cloned into a pIRES-puro3 vector.

All cell lines expressing a PrPC with a mutated

5C6 epitope could be detected by mab 6H4 (Figure 3.1A). However, only wild
type PrP, but not mutated PrPs could be detected by mAb 5C6 (Figure 3.1B).
These results demonstrate that the mutated constructs were successfully
expressed in the RK13 cells and that mutation of either alanine or asparagine is
sufficient to abolish 5C6 recognition.

It also confirmed the epitope of mAb 5C6

we described in section 1.

In order to determine susceptibility of the mutated mouse PrP or elk PrP in RK 13
cells to prions, we infected these cells with appropriate strains: mouse-adapted
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RML scrapie prions in the case of cells expressing MoPrP variants and CWD
isolate bala05 in the case of cells expressing elkPrP variants.

The infected

cultures were passaged three times in order to reduce detectable PrPSc from
infection.

Previous experiment showed infection of cells with RML or CWD

resulted in detectable PrPSc, however, there is a progressive reduction of PrPSc
after repeated passage (Bian, Napier et al. 2010). To analyze mouse PrPSc and
elk PrPSc by western blotting, detergent extracts containing equal amounts of
protein were treated with PK and centrifuged for 1 hour at 100,000 x g.

This high

speed centrifugation pelleted insoluble PrPSc molecules. We used proteinase K
to detect the PrPSc formation in culture. In mouse cell lines, we detected PrPSc
molecules in wild type mouse PrP after treating cultures with mouse-adapted RML
scrapie prions but not in the RK13 cells expressing empty pIRES vector.

Mouse

PrPC with an amino acid switch from asparagine to serine does not affect the
conversion ability from mouse PrPC to mouse PrPSc.

However substituting

alanine to valine at residue 132 in mouse PrP affects the susceptibility to RML
(Figure 3.2).

In elk cell lines, no PrPSc was detected in mutated elk PrP

constructs but wild type elk PrP (Figure 3.3) did show PrPSc formation.
Substituting alanine with valine in mouse PrP at position 132 affects mouse PrPSc
formation and substituting the same position in elk PrP also affects elk PrPSc
formation. The residue 132 in mouse PrP corresponding to residue 136 in sheep
PrP is a polymorphism in sheep PrP.

A previous report showed that sheep with

valine at residue 136 had higher susceptibility to scrapie compared to sheep with
alanine at residue 136 (Acin, Martin-Burriel et al. 2004). This indicated that the
alanine at residue 132 in mouse PrP might be involved in the conversion of PrPC
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to PrPSc and also implicated it as a residue responsible for the species barrier
between mouse and sheep.

Substituting asparagine with serine in mouse PrP at

position 158 does not affect mouse PrPSc formation but substituting the same
position in elk PrP affects elk PrPSc formation.
species specific.
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This indicated these residues are

Figure 3.1 Western blot analysis of RK13 cells expressing mutated elk or
mouse PrP to assess 5C6 reactivity. To assess the 5C6 epitope, the potential
epitope was introduced or eliminated from elk or mouse constructs. The
constructs were cloned into pIRES-Puro3 and transfected into rabbit kidney cells
(RK13) that do not express endogenous PrP. RK-Vector is negative control
expressing pIRES vector only. RK-MoPrP denotes RK13 cells expressing full
length of mouse PrP. RK-ElkPrP denotes RK13 cells expressing full length elk PrP.
RK-ElkPrP-A133V denotes RK13 cells expressing elk PrP with substitution
alanine to valine at residue 133. RK-ElkPrP-N162S denotes RK13 cells
expressing elk PrP with substitution arginnine to cystine at residue 162.
RK-MoPrP-A132V denotes RK13 cells expressing mouse PrP with substitution
alanine to valine at residue 132. RK-MoPrP-N158S denotes RK13 cells
expressing mouse PrP with substitution arginnine to cystine at residue 158.
Membranes were probed with (A) mouse monoclonal Ab 6H4 at 1:10,000 dilution
and (B) mouse monoclonal Ab 5C6 at 1:20 dilution. Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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Figure 3.2 Western blot analysis of conversion ability of mutated mouse PrP
expressed in RK13 cells. To detect the ability of PrPC to PrPSc conversion in
mutated mouse PrPs, the cells were infected with RML brain homogenate. RKV is
negative control expressing pIRES vector in RK13 cells. RKM denotes RK13 cells
expressing full length of mouse PrP. RKM-A132V denotes RK13 cells expressing
mouse PrP with substitution alanine to valine at residue 132. RKM-N158S
denotes RK13 cells expressing mouse PrP with substitution arginnine to cystine
at residue 158. The first six lanes are the cell lines without infection. All lines were
challenged with 0.1% RML brain homogenate. Cell lysates were collected with
cold lysis buffer from 10 cm culture plate at passage 3. Total protein content was
measured by bicinchoninic acid assay (BCA). Cell lysates detergent extracts
containng equal amounts protein were treated with 30 mg/ml PK for 1 hr at 37C
and centrifuge for 1 h at 100,000 x g. Membranes were probed with mouse
monoclonal Ab 6H4 at 1:10,000 dilution . Secondary antibody: HRP-conjugated
anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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Figure 3.3 Western blot analysis of conversion ability of mutated elk PrP in
RK13 cells. To detect the ability of PrPC to PrPSc conversion in new construct, the
cells were infected with CWD brain homogenate isolate Bala 05. RKV is negative
control expressing pIRES vector in RK13 cells. RKE denotes RK13 cells
expressing full length elk PrP. RKE-A133V denotes RK13 cells expressing elk PrP
with substitution alanine to valine at residue 133. RKE-N162S denotes RK13 cells
expressing elk PrP with substitution arginnine to cystine at residue 162. The first
six lanes show the cell lines without infection. Those cell lines indicated were
infected with 1/% CWD brain homogenate isolate Bala 05. Cell lysates were
collected with cold lysis buffer from 10 cm culture plate at passage 3. Cell lysates
were collected with cold lysis buffer from 10 cm culture plate at passage 3. Total
protein content was measured by bicinchoninic acid assay (BCA). Cell lysates
detergent extracts containng equal amounts protein were treated with 30 mg/ml
PK for 1 hr at 37C and centrifuge for 1 h at 100,000 x g. Membranes were probed
with mouse monoclonal Ab 6H4 at 1:10,000 dilution . Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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B. The deletion of residue 93 in mouse PrP affects the susceptibility of RML
infection in cell culture model
Based on the previous western blot analysis, mAb 9E9 is specific to the C2
fragment and has narrow specificity for cervid PrP (Figure 2.9). The epitope for
9E9 appears to be comprised of GQGGTH in elk and deer PrP. Mouse PrP at
the same location has the sequence of GQGGGTH.

There is one extra glycine

in mouse PrP. To confirm that this epitope constituted the 9E9 recognition
sequence we introduced an extra G in elk PrP and eliminated the corresponding
G in MoPrP via mutagenesis. We supposed that glycine at residue 93 in mouse
PrP interrupts 9E9’s binding with mouse PrP. We successfully transfected and
expressed all wild type PrPs and variants in RK13 cells as seen via blotting with
mAb 6H4 (Figure 3.4A).
successfully.

All PrPC can be detected by mAb 6H4 indicating all

Mouse PrP with one glycine deletion at position 93 was recognized

by mAb 9E9, and elk PrP with one glycine insertion at same position did not react
with mAb 9E9 (Figure 3.4B). This result showed that this extra glycine in mouse
PrP inhibits 9E9 recognition.

We also would like to determine the susceptibility of the established cell lines to
prions. The cell lines expressing elk and mouse PrPC and their mutated
counterparts were also infected with appropriate strains in order to assess the
ability of mutated PrPC to be converted to PrPSc.

RML inoculums were used to

infect cells expressing mouse PrP and its mutant, and CWD inoculums were used
to infect cells expressing cervid PrP and its mutant. All the samples were
prepared as described in previous studies. Consistent with the 5C6 result in
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mutated elk cell lines, we did not observe PrPSc from cells expressing elk PrP with
the insertion of glycine but did see conversion in wild type elk PrP (Figure 3.5).
However, we did detect the PrPSc from cells expressing mutated mouse PrP
containing 9E9 epitope and wild type mouse PrP(Figure 3.6).

Interestingly, we

could not detect the diglycosylated form of PrPSc in the mutated mouse PrP which
contained the 9E9 epitope. These results demonstrated that an extra glycine in
mouse PrP sequence is sufficient to interrupt 9E9 recognition. Producing 9E9
epitope by deleting this one extra glycine in mouse PrP does not prevent
formation of mouse PrPSc but decreases formation of di-glycosylated PrPSc.
Inserting one extra glycine at position 93 in elk PrP both interferes with 9E9
recognition and affects elk PrPSc formation.
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Figure 3.4 Western blot analysis of RK13 cells expressing mutated elk or
mouse PrP to assess 9E9 reactivity To assess the 9E9 epitope, the potential
epitope was introduced or eliminated from elk or mouse constructs. The
constructs were cloned into pIRES-Puro3 and transfected into rabbit kidney cells
that do not express endogenous PrP. RK-Vector is negative control expressing
pIRES vector only. RK-MoPrP denotes RK13 cells expressing full length of mouse
PrP. RK-ElkPrP denotes RK13 cells expressing full length elk PrP.
RK-ElkPrP-93G denotes RK13 cells expressing elk PrP with a glycine after
residue 93. RK-MoPrP-93G denotes RK13 cells expressing mouse PrP with
glycine deletion at residue 93. Membranes were probed with (A) mouse
monoclonal Ab 6H4 at 1:10,000 dilution and (B) mouse monoclonal Ab 9E9 at 1:5
dilution. Secondary antibody: HRP-conjugated anti-mouse (GE) at 1:5,000
dilution. Blots were developed with chemiluminescence (GE) and visualized via
Fuji scanner
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Figure 3.5 Western blot analysis of conversion ability of mutated elk PrP in
RK13 cells. To assess the ability of PrPC to convert to PrPSc , the transfected cells
were infected with CWD brain homogenate isolate Bala 05. RK-V is negative
control expressing pIRES vector in RK13 cells. RKE denotes RK13 cells
expressing full length elk PrP. RKE-93G denotes RK13 cells expressing elk PrP
with a glycine after residue 93. The first four lanes indicate cell lines without CWD
infection. Those cell lines indicated were infected with 1/% CWD brain
homogenate isolate Bala 05. Cell lysates were collected with cold lysis buffer from
10 cm culture plate at passage 3. Total protein content was measured by
bicinchoninic acid assay (BCA). Cell lysates detergent extracts containng equal
amounts protein were treated with 30 mg/ml PK for 1 hr at 37C and centrifuge for
1 h at 100,000 x g. Membranes were probed with mouse monoclonal Ab 6H4 at
1:10,000 dilution. Secondary antibody: HRP-conjugated anti-mouse (GE) at
1:5,000 dilution. Blots were developed with chemiluminescence (GE) and
visualized via Fuji scanner
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Figure 3.6 Western blot analysis of conversion ability of mutated mouse PrP
in RK13 cells. To detect PrPC to PrPSc conversion in new constructs, the cells
were infected with transgenic mice adapted RML brain homogenate. The
constructs were cloned into pIRES-Puro3 and transfected into rabbit kidney cells
that do not express endogenous PrP. RKV is negative control expressing pIRES
vector in RK13 cells. RKM denotes RK13 cells expressing full length of mouse
PrP. RKM-93G denotes RK13 cells expressing mouse PrP with glycine deletion
at residue 93. The first four lanes indicate cell lines without RML infection. Those
cell lines indicated were infected with 0.1% RML brain homogenate. Red square
indicates the location of diglycosylated PrP. Cell lysates were collected with cold
lysis buffer from 10 cm culture plate at passage 3. Total protein content was
measured by bicinchoninic acid assay (BCA). Cell lysates detergent extracts
containng equal amounts protein were treated with 30 mg/ml PK for 1 hr at 37C
and centrifuge for 1 h at 100,000 x g. Membranes were probed with mouse
monoclonal Ab 6H4 at 1:10,000 dilution Secondary antibody: HRP-conjugated
anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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C. Confirmation of potential epitope of mAb 7H11 and mAb 9H9
In section 1, we found 7H11 could not recognize bovine PrP and has weaker
reactivity with human PrP. We also found the binding ability of 7H11 was
affected by N-linked oligosaccharides and disulfide bridge.

Based on these

results, we hypothesized the epitope of mAb 7H11 is located at residue 166 and
197 of BoPrP. To further ascertain the recognition site of mAb 7H11, we mutated
BoPrP at residue 197 from glutamic acid to glutamine. This construct was
referred to BoPrP-E197Q. This residue is unique in bovine PrP sequence
compare to other mammals PrP sequence and our immunogen.

The

corresponding amino acids were also mutated from glutamine to glutamic acid at
residue 185 in mouse PrP to eliminate the 7H11 epitope. This construct was
referred to MoPrP-Q185E. These two mutated constructs were cloned into
pIRES-Puro3 vector and used to generat cell lines in RK13 cells.

Bovine

PrP-E197Q and mouse PrP-Q185E were examined via western blot with mAb
7H11.

As expected, mAb 7H11 lost its affinity for mouse PrP when the

substitution at 185 was made.

Mutating Bovine PrP to the mouse sequence at

residue 197 (bovine numbering) did not confer 7H11 binding.

Ongoing studies

are investigating the importance of amino acid 166 (bovine numbering) in the
ability of mAb 7H11 to recognize Bovine PrP.

In the previous mapping results, the epitope of mAb 9H9 is located at the
C-terminus of mouse PrP (Figure 2.16).

The unique amino acid sequence of

mouse and Syrian hamster PrP in the C-terminus is DGRRS which coincides with
the immunogen used to generate our antibodies, shuffled PrP#68. In the same
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region of other mammals’ PrPs, the amino sequence is QRG.

To clarify the

binding site of 9H9 and generate a cervid cell line that could be recognized by
mAb 9H9, three mutant cervid RK13 cell lines were generated by mutating QR to
DGRR, RR or DGQR starting from residue 230 based on the alignment of
mammalian PrP. These constructs are referred to as ElkPrP-QR230DGRR,
ElkPrP-QR230RR, and ElkPrP-QR230DGQR. We substituted residue 230Q and
231R in elk PrP sequence to DGRR to make the sequence the same as mouse
PrP and our immunogen.

To define the 9H9 recognition site more precisely, two

other constructs were generated, ElkPrP-QR230RR, and ElkPrP-QR230DGQR.
All mutated constructs and wild type were expressed successfully in RK13 cells
as seen via western blotting with mAb 6H4 (Figure 3.7A).

Only one mutant,

QR230DGRR, showed reactivity with mAb 9H9, but it was extremely weak (Figure
3.7B). In figure 3.7A, mutated elk PrPs have lower expression levels as compared
to wild type elk PrP.
cell culture samples.

In our previous experience, mAb 9H9 has low affinity with
The low expression level of the mutated elk PrPs in RK13

cells coupled with 9H9’s low affinity with cell culture samples could explain the
weak reactivity seen in figure 3.7B.

However, it is also possible that there are

other amino acids which might be involved in the reactivity of 9H9.
the extreme C- terminus might be necessary for 9H9 binding.
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The serine in

Figure 3.7 Western blot analysis of RK13 cells expressing mutated elk or
mouse PrP to assess 9H9 reactivity. Monoclonal antibody 9H9 has a specific
reactivity with mouse and Syrian hamster. To assess the 9H9 epitope, the
proposed epitope was introduced into elk constructs. The constructs were cloned
into pIRES-Puro3 and transfected into RK13 rabbit kidney cells that do not
express endogenous PrP. RK-Vector indicates negative control expressing pIRES
vector in the RK13. RK-ElkPrP denotes RK13 cells expressing full length of elk
PrP. RK-ElkPRP-QR230DGRR denotes RK13 cells expressing elk PrP with
amino acids substitution QR with DGRR from residue 230. RK-ElkPrP-QR230RR
is RK13 cell expressing elk PrP with amino acids substitution with QR with RR
from residue 230. RK-ElkPrP-QR230DGQR denotes RK13 cell expressing elk
PrP with amino acids substitution QR with DGQR from residue 230. Membranes
were probed with (A) mouse monoclonal Ab 6H4 at 1:10,000 dilution and (B)
mouse monoclonal Ab 9H9. Secondary antibody: HRP-conjugated anti-mouse
(GE) at 1:5,000 dilution. Blots were developed with chemiluminescence (GE) and
visualized via Fuji scanner
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Section 3: Structure analysis via deletion
Despite having the same sequence, PrPC and PrPSc are quite different both
structurally and biochemically.

To elucidate the mechanism of conversion of

PrPC to PrPSc has being a long-standing goal in prion disease research.
Conformational change from PrPC to PrPSc results in a higher percentage of beta
sheet structure and increased protease resistance. In an attempt to acquire
information from PrP’s primary structure regarding conformational changes during
conversion, we generated a series of ten contiguous amino acids deletion
constructs spanning amino acids 107 to 230 to find out which region is involved in
the conformational change (Figure 4.1).

Amino acids 107 to 230 in mouse PrP is

a region containing secondary structure and post-modifications.

I used these

previously generated deletion constructs for mapping our novel monoclonal
antibodies.

Figure 4.1 shows the scheme of the serial deletion constructs we

made and the location of glycosylation sites and cysteines involved in disulfide
bonding.

Also it indicates what secondary structure is lacking in each deletion

construct. All the deletion constructs were made via mutagenesis and cloned
into pIRES-puro3 vector (Invitrogen).

These constructs were transfected into RK

13 cells and expression was checked via immunoblotting with monoclonal
antibody R1 (Figure 4.2).

R1 was generated by immunization with PrP

liposomes and recognizes residues 225 to 230 in the C-terminus of PrP
(Williamson, Peretz et al. 1998).

In other words, R1 recognized all the deletion

constructs except MoPrP222-230 which includes recognition site of R1.

One of

the N-linked oligosaccharide sites is in the deletion mutant 192-201and has been
65

removed; therefore this mutant has lower molecular weight than other deletion
mutants. When we analyzed these cell lines with mAb 6H4, not only the deletion
which encompasses its epitope site, but also other deletions in the central region
of construct lacked reactivity (Figure 4.3). Most of the deletions from 141 to 221
have no reactivity with mAb 6H4, Only MoPrP182-191 and MoPrP192-201
have very weak reactivity.

Based on sections 1 and 2, we know the epitope of

mAb 5C6 is at residue 132 and 158 of MoPrP.

Therefore, we expected there to

be no reactivity with MoPrP132-141 or MoPrP152-161.
constructs with deletions ranging
mAb 5C6 (Figure 4.4).

Surprisingly,

from 121 to 221 showed no recognition with

We continued to analyze our in-house monoclonal

antibodies with these constructs expressing in RK 13 cells.
detect mouse PrP, so we did not use for analysis.

MAb 9E9 is does not

The 7H11 epitope is stericially

hindered by N-linked oligosaccharides and 7H11 binding is increased in the
presence of the disulfide bond.

7H11 has two epitopes, residue 154 and 185 (in

mouse numbering) (Figure2.14). We observed hindrance effects in
MoPrP141-151 to MoPrP211-221 with 7H11 (Figure 4.5). As we expected,
MAb 9H9 recognized all the deletion constructs excepting MoPrP222-230 which
contains the 9H9 epitope.

Only antibodies with epitopes in the C-terminus of PrP

meet our expectation that the antibody will recognize all deletions except for that
which encompasses its epitope.

We wondered if post-translational modifications in mammalian cells could
influence the antibody binding capacity in our deletion constructs. To address
this question, we transferred all deletion constructs into pET-100 vector and
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expressed them in a bacterial system. In the bacterial system, there is no
post-translational modification, but proteins do form secondary structure and
disulfide bonds.

Since the 6H4 epitope lies somewhere between amino acids

144 and 152 we hypothesized that the deletion mutants 142-151 and 152-161
would not be recognized by 6H4. As we expected, mAb 6H4 recognized all the
constructs excepted for deletions including the binding region in the bacterial
system (Figure 4.7). However, when we detected these constructs with other
antibodies, we observed an epitope shielding phenomenon, as in the mammalian
system.

In the western blot, most of the deletion constructs with deletions from

the central region of 132 to 221 had no reactivity with mAb 5C6 (Figure 4.8).
Only MoPrP182-191 had slight reactivity with 5C6. When analyzing mAb 7H11
with these constructs in bacterial system, 7H11 recognized wild type recombinant
mouse PrP and some deletion constructs but did not have reactivity with the
constructs containing deletions close to the 7H11 epitope (Figure 4.9).

MAb 9H9

recognized wild type PrP and all the deletion constructs except MoPrP222-230,
just as in the mammalian cells (Figure 4.10). However, the binding reactivity of
9H9 with recombinant protein is stronger than it is with mammalian cell lysates.
Comparing western blots probed with 9H9 or other monoclonal antibodies, we
confirmed the binding site of 9H9 is located in the C-terminus of PrP.

Since mAb

5C6 recognizes alanine at position 132 and asparagines at position 158 in mouse
PrP, it is a conformation dependent monoclonal antibody, as is 7H11.

Routinely,

before performing gel electrophoresis, all samples are mixed with denaturing
reagents like sodium dodecyl sulfate (SDS), an anionic detergent which
denatures secondary and non–disulfide–linked tertiary structures, and applies a
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negative charge to each protein in proportion to its mass. Traditional wisdom
dictates that conformation dependent monoclonal antibodies cannot detect
proteins which are denatured.

However, in our western blot results, we can

detect wild type mouse PrP with our conformation dependent monoclonal
antibodies, 5C6 and 7H11.

That indicates that the structured region of PrP forms

a very stable structure that cannot be denatured by a detergent like SDS.

The

eptiopes of 9H9 or R1 are in the unstructured C-terminus region, which can be
recognized.
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Figure 4.1 The scheme of the serial deletion constructs
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Figure 4.2 Western blot analysis of serial deletion constructs in mammal
cell line with R1. All deletion constructs were cloned into pIRES-Puro3 and
transfected into RK13 cells. Cell lysates were collected with cold lysis buffer from
10 cm culture plate. Total protein content was measured by bicinchoninic acid
assay (BCA). Each well was loaded 50ug cell lysate. Membrane was probed
with anti-PrP R1 at 1:10,000 dilution which epitope is 225 to 230. Secondary
antibody: HRP-conjugated anti-human (pierce) at 1:5,000 dilution. Blots were
developed with chemiluminescence (GE) and visualized via Fuji scanner
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Figure 4.3 Western blot analysis of serial deletion constructs in mammal
cell line with 6H4. All deletion constructs were cloned into pIRES-Puro3 and
transfected into RK13 cells. Each well was loaded 50µg cell lysate. Membrane
was probed with anti-PrP 6H4 with 1:10000 dilutions which epitope is from 144 to
152. Secondary antibody: HRP-conjugated anti-mouse (GE) at 1:5,000 dilution.
Blots were developed with chemiluminescence (GE) and visualized via Fuji
scanner
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Figure 4.4 Western blot analysis of serial deletion constructs in mammal
cell line with 5C6. All deletion constructs were cloned into pIRES-Puro3 and
transfected into RK13 cells. Each well was loaded 50µg cell lysate. Membrane
was probed with mouse monoclonal Ab 5C6 at 1:20 dilution. Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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Figure 4.5 Western blot analysis of serial deletion constructs in mammal
cell line with 7H11. All deletion constructs were cloned into pIRES-Puro3 and
transfected into RK13 cells. Each well was loaded 75µg cell lysate. Membrane
was probed with mouse monoclonal Ab 7H11 without dilution. Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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Figure 4.6 Western blot analysis of serial deletion constructs in mammal
cell line with 9H9. All deletion constructs were cloned into pIRES-Puro3 and
transfected into RK13 cells. Each well was loaded 75µg cell lysates. Membrane
was probed with mouse monoclonal Ab 9H9 without dilution. Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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Figure 4.7 Western blot analysis of serial deletion constructs in bacterial
system via 6H4. All deletion constructs were cloned into pET-100 and
transformed into BL21. Seed 1:50 dilution overnight bacterial broth and grow until
OD 600 reach 0.6. Added 1mM IPTG into broth and grew for 4 hours. Collected 1
ml induced bacteria cell lysate and mixed with 100 µl 1X loading buffer. Each
well was loaded 5µl cell lysate. Membrane was probed with anti-PrP 6H4 with
1:10000 dilutions which epitope is from 144 to 152. Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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Figure 4.8 Western blot analysis of serial deletion constructs in bacterial
system via 5C6. All deletion constructs were cloned into pET-100 and
transformed into BL21. Each well was loaded 5µl cell lysate. Membrane was
probed with mouse monoclonal Ab 5C6 with 1:20 dilution. Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner

76

Figure 4.9 Western blot analysis of serial deletion constructs in bacterial
system via 7H11. All deletion constructs were cloned into pET-100 and
transformed into BL21. Each well was loaded 5µl cell lysate. Membrane was
probed with mouse monoclonal Ab 7H11 without dilution. Secondary antibody:
HRP-conjugated anti-mouse (GE) at 1:5,000 dilution. Blots were developed with
chemiluminescence (GE) and visualized via Fuji scanner
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Figure 4.10 Western blot analysis of serial deletion constructs in bacterial
system via 9H9. All deletion constructs were cloned into pET-100 and
transformed into BL21. Lane 1 is expressing pET-Vector in BL-21. Each well
was loaded 5 µl cell lysate. Membrane was probed with mouse monoclonal Ab
9H9 without dilution. Secondary antibody: HRP-conjugated anti-mouse (GE) at
1:5,000 dilution. Blots were developed with chemiluminescence (GE) and
visualized via Fuji scanner
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Chapter 4
Discussion

Prions are transmitted in an unconventional way via a protein particle without
nucleic acids.

It is still mysterious and many aspects are as yet unknown.

Most anti-PrP antibodies are expensive.

Conformational change is a major

component in the mechanism of prion replication. The two forms of PrP share
the same amino acid sequence, but have drastically different biochemical
properties.

In an attempt to acquire more information on the conversion process,

such as key sites, we created novel sequences containing mouse and elk PrP via
shuffling of the two species’ PrP DNA sequences. In the hopes that we could
generate new and novel prion antibodies to answer some of the mysteries
surrounding the conversion process, we used three of our shuffled DNA
constructs as immunogen for in-house antibody production. These three
constructs were selected for producing immunogen, because their equences are
distributed equally between mouse and elk PrP.

Using these new PrP

sequences which mixed mouse and elk PrP, we generated a series of monoclonal
antibodies with novel epitopes. We collected all the hybridoma cells generated
by three shuffled PrP with novel sequence.
fifty hybridoma cells.
shuffled PrP#68.

Each shuffled PrP produced thirty to

We only screened those hybridoma cells generated by

Four novel mAbs have been characterized and each of them

has unusual and useful properties. They are 5C6, 9E9, 7H11 and 9H9.
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MAb 5C6 reacts efficiently with PrPs from a broad range of mammalian species
including mouse, deer, elk, bovine, equine, human, Syrian hamster, mink, ferret,
and sheep with alanine in residue 136.

According to the sequence of sheep

(VRQ) and squirrel monkey, residues 132 alanine and 158 asparagine are
necessary for 5C6 binding. We confirmed this when we substituted alanine with
valine at position 132 or asparagine with serine at position 158 in mouse PrP and
the same position in elk PrP.

There are 26 amino acids between these two

binding sites. This indicated that 5C6 is a conformation dependent mAb.
These two recognition sites span the base of the loop between 1 and 2 and are
close to each other when the protein is folded.

To investigate the role of the 5C6

epitope, we expressed these mutated mouse PrP variants or mutated elk PrP
variants in the RK13 cells and infected with proper prions.

Substituting alanine

with valine in mouse PrP at position 132 affects mouse PrPSc formation and
substituting the same position in elk PrP also affects elk PrPSc formation. Residue
132 in mouse PrP corresponds to residue 136 in sheep PrP. This residue is also
one polymorphism of sheep PrP.

A previous report showed that sheep PrP with

valine at residue 136 has higher susceptibility to scrapie compared to sheep PrP
with alanine at residue 136 (Acin, Martin-Burriel et al. 2004). That indicated the
alanine at residue 132 in mouse PrP might be involved in the conversion of PrPC
to PrPSc and might be the amino acid that results in the species barrier between
mouse and sheep. To prove this assumption, we can infect the cell line,
RK-MoPrPA132, with sheep scrapie.

If this cell line can be infected by sheep

scrapie, then it indicates residue 132 in mouse PrP is the key site for species
barrier between sheep and mouse or other mammals. It is possible because
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most other mammals PrP sequence have alanine at that position. Substituting
asparagine with serine in mouse at position 158 does not affect mouse PrPSc
formation but substituting the same position in elk PrP affects elk PrPSc formation.
This indicated these residues are species specific.

Even when expressing the

same amino acid in the same position, it shows a species specific role.

Since

this substitution does not affect mouse PrPSc formation, it would be useful to use
this 5C6 epitope negative mouse PrP in the scrapie cell assay (Klohn, Stoltze et al.
2003; Bian, Napier et al. 2010). We coule differentiate the wild type and mutated
form by using our novel mAb 5C6.

MAb 9E9 has narrow specificity and only has strong affinity for cervid PrP.

It has

less affinity with horse and sheep PrP. It might be influenced by the amino acid
serine after glycine at position 93, because in elk PrP and our immunogen
shuffled PrP #68, there is threonine after glycine at position at 92. 9E9 epitope is
adjacent to C2 cleavage site; an extra glycine in mouse PrP sequence interrupts
the 9E9 recognition. It was confirmed when we deleted glycine in mouse PrP at
position 93 or inserted one glycine at the same position in elk PrP. When we
produced the 9E9 epitope by deleting one glycine in mouse PrP, it did not prevent
formation of mouse PrPSc but decreased formation of di-glycosylated PrPs.
Does the 9E9 tag in this mutated mouse PrP influence the PK digestion site?
Several studies suggest that either helix 1 (residues 144–154) or the 90–145 part
of the PrP protein plays a critical role in the conversion process to a β-sheet
structure (Peretz, Williamson et al. 1997; Zhang, Stockel et al. 1997; Glockshuber,
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Hornemann et al. 1998; Morrissey and Shakhnovich 1999).

It would be

interesting to engineer a transgenic mouse with this 9E9-postive mouse PrP and
inoculate with mouse prion.

Inserting one glycine at position 93 in elk PrP affects

elk PrPSc formation. This indicated that the sequence between C1 and C2
cleavage sites might be involved in the conversion of PrPC to PrPSc

The binding ability of mAb 7H11 is sterically affected by the secondary structure of
PrP.

It recognizes mouse, elk, deer, and sheep and has weak affinity to human

PrP.

It does not recognize bovine PrP.

The binding capacity of 7H11 was

affected by the presence of two N-linked glycans and the disulfide bond.
According to these results, we supposed one of the epitopes of mAb 7H11 is
between the two N-linked glycosylation sites, the other epitope is located 30
amino acids away in the upstream of the sequence.

This indicated that 7H11 is

also a conformation dependent mAb. We do not have more results to assure the
exact recognition site of 7H11 at this stage.
MAb 9H9 has narrow species specificity since it only reacts with mouse and
hamster PrP. We only know this antibody recognized the end of C-terminus PrP
and it has mouse specificity.

If we can clarify the exact residues, it could be a

great tool to study mouse PrP.
To further understand the mechanism of conversion and characterize the
structure of Prions, we generated an array of mutated PrPs with contiguous ten
amino acids deletion constructs across the structured region of PrP (amino acids
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107 to 230). This region contains the alpha-helix, beta-sheet, and
post-translational modifications like glycosylation. These deletion constructs
provide a way to map our novel monoclonal antibodies. The western blot
analysis gave us the surprising result that the folded structure of wild type PrP is
ultra-stable, even when we treated our sample with a detergent like SDS and ran
our gel under denaturing conditions.

If we deleted 10 amino acids within the

c-terminal region, it caused instability in the structure and had effects on antibody
recognition.
We created four novel mAbs and each of them has unusual and useful properties.
We can study prion replication from these novel epitopes. They will be helpful in
studying prion pathogenesis.
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